Form 4: Director Gilliland Acquires ADIL Pharmaceuticals Stock

Robertson H. Gilliland, a Director at ADIAL PHARMACEUTICALS, INC., reported the acquisition of 9,185 shares of common stock on April 7, 2026.

Summary

• Director Robertson H. Gilliland acquired 9,185 shares of ADIAL PHARMACEUTICALS, INC. common stock on April 7, 2026.
• This acquisition was made through a grant of restricted shares.
• The shares vest in full on the earlier of the one-year anniversary of the grant date or a Change of Control, provided the reporting person continues to serve the issuer.
• The reported transaction has a value of $0, indicating it was likely a stock grant rather than a purchase.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard stock grant to a director rather than a purchase or sale of shares on the open market.

Positives

• Director acquisition of shares can signal confidence in the company's future prospects.
• The grant of restricted shares indicates a form of executive compensation tied to continued service and potential company events like a Change of Control.

Risks

• The vesting of shares is contingent upon continued service, meaning departure from the company before the vesting date would result in forfeiture.
• A Change of Control event, while potentially beneficial for shareholders, could also signal underlying issues or strategic shifts within the company.

Future Outlook

The future outlook for the acquired shares is tied to the vesting schedule, which depends on continued service of the reporting person and potential future corporate events such as a Change of Control.

Industry Context

StockSavvy.ai notes that insider transactions, particularly grants of restricted stock to directors, are common in the pharmaceutical industry as a means to align executive interests with long-term company performance and shareholder value.

Related Party Transactions

• The reported transaction is a grant of restricted shares to Director Robertson H. Gilliland, which is a form of compensation and a related party transaction.

Stakeholder Impact

• Shareholders: The acquisition by a director may be viewed positively, suggesting confidence in the company. However, the nature of the grant (restricted stock with vesting conditions) means it doesn't represent an immediate market purchase.
• Employees: The grant is part of the company's equity incentive plan, which can impact employee morale and retention if seen as fair and competitive.
• Management: The grant is a form of compensation for management, aligning their interests with the company's long-term success.

Next Steps

• The restricted shares will vest in full on the earlier of the one-year anniversary of the grant date or a Change of Control.
• Continued service by the reporting person through the vesting date is required for the shares to vest.

Key Dates

Keywords

ADIAL PHARMACEUTICALS, ADIL, Form 4, SEC Filing, Insider Trading, Stock Grant, Restricted Stock, Director Compensation, Beneficial Ownership, Equity Incentive Plan